Skip to main content
. 2021 Oct 20;11:756326. doi: 10.3389/fonc.2021.756326

Figure 2.

Figure 2

Construction of the six-CpG-scorer in training set. (A) Venn diagram of the overlap between differentially methylated CpGs between different HCC BCLC stages (0-C) and CHB. (B) Fivefold CV LASSO coefficients of 34 candidate CpGs. The first black vertical dotted line corresponds to the λmin that minimized binomial deviance during CV. The second black vertical dotted line corresponds to λ1se, used for the selection of six biomarker CpGs. (C) LASSO coefficient profile of the 34 early HCC-associated CpGs. A vertical line was drawn at the value chosen by fivefold cross-validation. (D) The six-CpG-scorer of each participant from the liver disease, early HCC group in the training dataset was calculated, and the score was significantly increased in the early HCC versus the HBV-related liver disease (HBVLD) samples (Wilcoxon rank sum test was used to compare six-CpG risk score between two groups). (E) Area under the receiver operating characteristic curve (AUROC) of the six-CpG-scorer and its component CpGs. Data were AUROC (95% CI). HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer staging system; LASSO, least absolute shrinkage and selection operator method.